-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Purinostat Mesylate in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Purinostat Mesylate in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Purinostat Mesylate in Diffuse Large B-Cell Lymphoma Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Purinostat Mesylate in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Purinostat Mesylate in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Purinostat Mesylate in Relapsed Multiple Myeloma Drug Details: Purinostat...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Purinostat Mesylate in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Purinostat Mesylate in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Purinostat Mesylate in Refractory Multiple Myeloma Drug Details: Purinostat...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Purinostat Mesylate in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Purinostat Mesylate in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Purinostat Mesylate in B-Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Purinostat Mesylate in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Purinostat Mesylate in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Purinostat Mesylate in T-Cell...
-
Company Insights
NewHartford Financial Services Group Inc. – Digital Transformation Strategies
Hartford Health Digital Transformation Strategies Overview Hartford is tapping the power of big data analytics to analyze data and generate insights, improve member engagement, and detect fraudulent claims. AI, big data, cloud, cybersecurity, and IoT are among the key technologies under focus for the company. The annual ICT spending of Hartford was estimated at $549 million in 2023. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. The Hartford Financial Services...
-
Company Insights
NewGrupo Financiero Banorte – Digital Transformation Strategies
Banorte Digital Transformation Strategies Overview Banorte has been investing in emerging technologies over the years to improve efficiencies, and product offerings, and streamline operations. AI, big data, cloud, and payments are among the key technologies under focus for the company. The annual ICT spending of Banorte was estimated at $503 million in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and network and communications from vendors. Grupo Financiero Banorte SAB de CV (GFNorte) is...
-
Company Insights
NewNestlé S.A. – Digital Transformation Strategies
Nestle Digital Transformation Strategies Overview Nestle has been focusing on using artificial intelligence, cloud-based mobile applications, big data, and augmented reality to digitally transform its operations. The annual ICT spending of Nestle was estimated at $1.4 billion for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Nestlé S.A. (Nestlé) is a food and beverages company, offering more than 2,000 branded products across 190 countries. The company classifies its business operations...
-
Company Insights
NewLVMH Moet Hennessy Louis Vuitton SE – Digital Transformation Strategies
LVMH Moet Hennessy Louis Vuitton SE Digital Transformation Strategies Overview LVMH has been focusing on using artificial intelligence, cloud-based mobile applications, and AR to digitally transform its operations. The annual ICT spending of LVMH was estimated at $1.3 billion for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. LVMH Moet Hennessy Louis Vuitton SE (LVMH) is a manufacturer and marketer of luxury goods. The company's product portfolio comprises clothing, fashion...
-
Thematic Analysis
NewState of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence
Reasons to buy the ‘State of the Biopharmaceutical Industry 2024’ thematic intelligence report: Highlight the business environment and the industry, regulatory, and macroeconomic trends that are going to shape the biopharmaceutical industry in the next 12 months. Benchmark the impact of major themes on the biopharmaceutical industry in the next 12 months, Identify themes that will have the greatest positive or negative impact in the coming months. Comprehend the opinions of industry respondents on these themes. Predict the industry’s growth prospects...